Report of the First ONTOX Stakeholder Network Meeting: Digging Under the Surface of ONTOX Together With the Stakeholders.

Journal: Alternatives to laboratory animals : ATLA
Published Date:

Abstract

The first Stakeholder Network Meeting of the EU Horizon 2020-funded ONTOX project was held on 13-14 March 2023, in Brussels, Belgium. The discussion centred around identifying specific challenges, barriers and drivers in relation to the implementation of non-animal new approach methodologies (NAMs) and probabilistic risk assessment (PRA), in order to help address the issues and rank them according to their associated level of difficulty. ONTOX aims to advance the assessment of chemical risk to humans, without the use of animal testing, by developing non-animal NAMs and PRA in line with 21st century toxicity testing principles. Stakeholder groups (regulatory authorities, companies, academia, non-governmental organisations) were identified and invited to participate in a meeting and a survey, by which their current position in relation to the implementation of NAMs and PRA was ascertained, as well as specific challenges and drivers highlighted. The survey analysis revealed areas of agreement and disagreement among stakeholders on topics such as capacity building, sustainability, regulatory acceptance, validation of adverse outcome pathways, acceptance of artificial intelligence (AI) in risk assessment, and guaranteeing consumer safety. The stakeholder network meeting resulted in the identification of barriers, drivers and specific challenges that need to be addressed. Breakout groups discussed topics such as hazard versus risk assessment, future reliance on AI and machine learning, regulatory requirements for industry and sustainability of the ONTOX Hub platform. The outputs from these discussions provided insights for overcoming barriers and leveraging drivers for implementing NAMs and PRA. It was concluded that there is a continued need for stakeholder engagement, including the organisation of a 'hackathon' to tackle challenges, to ensure the successful implementation of NAMs and PRA in chemical risk assessment.

Authors

  • Michael G Diemar
    3Rs Management and Consulting ApS, Kongens Lyngby, Denmark.
  • Mathieu Vinken
    Department of In Vitro Toxicology and Dermato-Cosmetology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium.
  • Marc Teunis
    Innovative Testing in Life Sciences & Chemistry, University of Applied Sciences, Utrecht, The Netherlands.
  • Cyrille A M Krul
    Innovative Testing in Life Sciences & Chemistry, University of Applied Sciences, Utrecht, The Netherlands.
  • François Busquet
    Altertox, Brussels, Belgium.
  • Julia Dominika Zajac
    Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussel, Belgium.
  • Helena Kandarova
    Centre of Experimental Medicine SAS, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Raffaella Corvi
    European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Matteo Z Rosso
    Angel Consulting S.a.S., Genova, Italy.
  • Anastasiia Kharina
    Angel Consulting S.a.S., Genova, Italy.
  • Louise Stab Bryndum
    Danish Environmental Protection Agency, Copenhagen, Denmark.
  • Michael Santillo
    Center for Food Safety and Applied Nutrition (CFSAN), US Food and Drug Administration (FDA), Laurel, MD, USA.
  • Denise Bloch
    Department of Pesticides Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
  • Olena Kucheryavenko
    Department of Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
  • Demosthenes Panagiotakos
    SCHEER/EC-Scientific Committee on Health, Environmental and Emerging Risks/European Commission, European Commission, Brussels, Belgium.
  • Vera Rogiers
    Scientific Committee on Consumer Safety (SCCS), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Manon Beekhuijzen
    Charles River Laboratories, 's-Hertogenbosch, The Netherlands.
  • Arianna Giusti
    Cosmetics Europe-The Personal Care Association, Brussels, Belgium.
  • Abdulkarim Najjar
    Beiersdorf AG, Hamburg, Germany.
  • Carol Courage
    International Collaboration on Cosmetics Safety (ICCS), Mt Royal, NJ, USA.
  • Torben Koenig
    International Collaboration on Cosmetics Safety (ICCS), Mt Royal, NJ, USA.
  • Susanne Kolle
    Experimental Toxicology and Ecology, BASF SE, Ludwigshafen am Rhein, Germany (for CEFIC).
  • Harrie Boonen
    H. Lundbeck, Valby, Denmark.
  • Stephane Dhalluin
    L'Oreal, Paris, France.
  • Julie Boberg
    Novo Nordisk, Bagsværd, Denmark.
  • Boris P Müller
    Symrise AG, Holzminden, Germany.
  • Predrag Kukic
    Safety & Environmental Assurance Centre, Unilever, Bedfordshire, UK.
  • Merel Ritskes-Hoitinga
    SYRCLE, Department for Health Evidence, 221034Radboudumc, Nijmegen, the Netherlands.
  • Elena Grasselli
    Department of Earth, Environment, and Life Science, University of Genoa, Genova, Italy.
  • Tamara Zietek
    Doctors Against Animal Experiments, Cologne, Germany.
  • Gilly Stoddart
    PETA Science Consortium International e.V., Stuttgart, Germany.
  • Harm J Heusinkveld
    Dutch National Institute for Public Health and the Environment, Centre for Health Protection, Bilthoven, The Netherlands.
  • Jose V Castell
    Department of Biochemistry, IIS Hospital La Fe and CIBERHED, University of Valencia, Valencia, Spain.
  • Emilio Benfenati
    Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy.
  • Huan Yang
  • Simón Perera
    ProtoQSAR SL, Centro Europeo de Empresas Innovadoras, Paterna, Spain.
  • Alicia Paini
    esqLABS GmbH, Saterland, Germany.
  • Nynke I Kramer
    Toxicology Chair Group, Wageningen University, Wageningen, The Netherlands.
  • Thomas Hartung
    Center for Alternatives to Animal Testing (CAAT), Health and Whiting School of Engineering, Johns Hopkins University, Baltimore, MD, United States.
  • Manoe Janssen
    The Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Ellen Fritsche
    IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany, and Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Danyel G J Jennen
    Dept. of Toxicogenomics, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
  • Matteo Piumatti
    Altertox, Ixelles, Belgium.
  • James Rathman
    Molecular Networks GMBH Computerchemie, Nuremberg, Germany.
  • Jörg Marusczyk
    Molecular Networks GMBH Computerchemie, Nuremberg, Germany.
  • Lucia Milec
    Institute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Erwin L Roggen
    3Rs Management and Consulting ApS, Kongens Lyngby, Denmark.